FrancophonIA/ELRC3.0 huggingface dataset:
English: Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 1090
Slovenian: Leptospira interrogans serološka skupina Canicola serovar Canicola, sev MSLB 1090
English: **Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.
Slovenian: **Relativna potenca pri testu potence pri miših v primerjavi z referenčnim cepivom, ki je bilo učinkovito pri ovcah.
English: EMEA Number Invented Name
Slovenian: EU številka Izmišljeno ime
English: Content Package size
Slovenian: Vsebina Velikost pakiranja
English: Page 2/2
Slovenian: str. 2/2
English: The final opinion was converted into a Decision by the European Commission on 30 April 2009.
Slovenian: Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 30. aprila 2009.
English: EMEA/681318/2008-EN
Slovenian: EMEA/681318/2008-SL
English: The assessment report and the opinion were transferred to the European Commission for decision.
Slovenian: Poročilo o oceni in mnenje so v odločanje predali Evropski komisiji.
English: London, 30 April 2009 EMEA/681319/2008
Slovenian: London, 30. aprila 2009 EMEA/681319/2009
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II.
Slovenian: Seznam zadevnih imen izdelkov je naveden v Dodatku I. Znanstveni zaključki so navedeni v Dodatku II.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
Slovenian: ODBOR ZA ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI (CVMP)
English: (International Non-Proprietary Name (INN): Xylazine, Medetomidine, Detomidine, Romifidine)
Slovenian: (Mednarodno nelastniško ime (INN): ksilazin, medetomidin, detomidin, romifidin)
English: The veterinarian experienced cardiovascular and central nervous system effects over a period of 3 days.
Slovenian: Pri veterinarju so bili naslednje tri dni prisotni učinki na srčno-žilni in osrednji živčni sistem.
English: Dr Anja Holm was appointed as Rapporteur and Dr Peter Ekström as Co-Rapporteur.
Slovenian: Kot poročevalka je bila določena dr. Anja Holm, kot soporočevalec pa dr. Peter Ekström.
English: No new substantial data was provided by any of the responding Marketing Authorisation Holders and therefore the assessment remains based on the data considered in 2006.
Slovenian: Nihče izmed imetnikov dovoljenj za promet z zdravilom ni predložil novih ključnih podatkov, zato ocena še vedno temelji na podatkih, ki so jih upoštevali leta 2006.
English: The Committee reconfirmed Dr A. Holm as Rapporteur and Dr P. Ekström as Co-Rapporteur for the procedure.
Slovenian: Odbor je ponovno potrdil dr. A. Holm kot poročevalko in dr. P. Ekströma kot soporočevalca v tem postopku.
English: Alpha2-adrenoreceptor agonists are pharmaceutically active substances that are commonly used to induce effects such as sedation, analgesia and muscle relaxation.
Slovenian: Agonisti adrenergičnih receptorjev alfa2 so farmacevtske zdravilne učinkovine, ki se navadno uporabljajo za sproženje učinkov, kot so sedacija, analgezija in sprostitev mišičja.
English: The CVMP concluded that, on the basis of the available data, there is at present a potential risk to human health posed by the use of products containing alpha2-adrenoreceptor agonists, and issued a revised opinion on 12 November 2008.
Slovenian: CVMP je na podlagi razpoložljivih podatkov zaključil, da trenutno obstaja morebitno tveganje za človeško zdravje, ki ga predstavlja uporaba zdravil, ki vsebujejo agoniste adrenergičnih receptorjev alfa2, in je dne 12. novembra 2008 izdal spremenjeno mnenje.
English: Additionally, the CVMP concluded that the need for updating the product literature to reflect the matters above is not urgent.
Slovenian: Poleg tega je CVMP zaključil, da ni potrebna takojšnja posodobitev gradiva zdravil, da bi vključevalo zgoraj navedeno.
English: Xylazine, detomidine, medetomidine and romifidine are alpha2-adrenoreceptor agonists.
Slovenian: Ksilazin, detomidin, medetomidin in romifidin so agonisti adrenergičnih receptorjev alfa2.
English: During its December 2006 meeting, the CVMP, in light of the overall data submitted, additional data from the public domain and the scientific discussion within the Committee, adopted by consensus an opinion concerning the 21 veterinary medicinal products as authorised in the Netherlands.
Slovenian: CVMP je na svojem zasedanju decembra 2006 ob upoštevanju vseh predloženih podatkov, dodatnih podatkov iz javne domene in znanstvene razprave znotraj Odbora soglasno sprejel mnenje glede 21 zdravil za uporabo v veterinarski medicini, odobrenih na Nizozemskem.
English: The basis for the notification was a suspected adverse reaction report received in The Netherlands after a veterinarian accidentally injected himself with the product Sedivet, which contains romifidine as the active ingredient.
Slovenian: Podlaga za obvestilo je bilo poročilo o sumu na neželene učinke, ki je bilo prejeto na Nizozemskem po tem, ko si je veterinar po nesreči vbrizgal zdravilo Sedivet, ki kot zdravilno učinkovino vsebuje romifidin.
English: OPINION FOLLOWING AN ARTICLE 781 PROCEDURE FOR Veterinary medicinal products containing Alpha2-adrenoreceptor agonists2
Slovenian: MNENJE V ZVEZI S POSTOPKOM V SKLADU S ČLENOM 781 ZA zdravila za uporabo v veterinarski medicini, ki vsebujejo agoniste adrenergičnih receptorjev alfa22
English: Written responses were received by Marketing Authorisation Holders for 81 of the 108 notified authorisations held by a total of 66 Marketing Authorisation Holders by 16 September 2008.
Slovenian: Imetniki dovoljenj za promet z zdravilom so do 16. septembra 2008 prejeli pisne odgovore za 81 od 108 priglašenih dovoljenj za promet z zdravilom, ki jih je imelo 66 imetnikov dovoljenj za promet z zdravilom.
English: In accordance with Article 78(3) of Directive 2001/82/EC, as amended, the Committee for Medicinal Products for Veterinary Use (CVMP) is to give its opinion on the conclusions and intended risk management measures presented by the notifying Authority which in this procedure was the Dutch Medicines Evaluation Board.
Slovenian: V skladu s členom 78(3) Direktive 2001/82/ES, kakor je bila spremenjena, mora Odbor za zdravila za uporabo v veterinarski medicini (CVMP) podati svoje mnenje o zaključkih in predlaganih ukrepih obvladovanja tveganj, ki jih je predstavil organ priglasitelj, kar je bil v tem postopku nizozemski odbor za ocenjevanje zdravil.
English: On 13 September 2006 the procedure was initiated by adoption of a list of questions to be put to the concerned Marketing Authorisation Holders.
Slovenian: Postopek se je začel 13. septembra 2006 s sprejetjem seznama vprašanj za zadevne imetnike dovoljenj za promet z zdravilom.
English: Member States identified and informed the Agency of the concerned marketing authorisations in their respective territories.
Slovenian: Države članice so identificirale zadevna dovoljenja za promet z zdravilom na svojih ozemljih in o tem obvestile Agencijo.
English: The concerned Marketing Authorisation Holders were informed accordingly by a letter dated 13 December 2006.
Slovenian: Zadevni imetniki dovoljenj za promet z zdravilom so bili ustrezno obveščeni z dopisom z dne 13. decembra 2006.
English: Following further communication with the European Commission in years 2007 and 2008 on the opinion and the scope of the procedure, the CVMP in the July 2008 plenary meeting agreed to complete the procedure under Article 78 of Directive 2001/82/EC, as amended, for all marketing authorisations held in the EU for the 21 products containing alpha2-adrenoreceptor agonists initially notified and to revise the initial opinion accordingly.
Slovenian: CVMP se je po nadaljnjem posvetovanju z Evropsko komisijo v letih 2007 in 2008 glede mnenja in obsega postopka na plenarnem zasedanju v juliju 2008 strinjal, da bo zaključil postopek v skladu s členom 78 Direktive 2001/82/ES, kakor je bila spremenjena, za vsa že priglašena dovoljenja za promet z zdravilom v EU za 21 zdravil, ki vsebujejo agoniste adrenergičnih receptorjev alfa2, ter da bo skladno s tem ponovno pregledal prvotno mnenje.
English: A revised list of questions addressed to the concerned Marketing Authorisation Holders was adopted on 16 July 2008.
Slovenian: Dne 16. julija 2008 je bil sprejet revidiran seznam vprašanj, naslovljen na zadevne imetnike dovoljenj za promet z zdravilom.
English: The College Ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board, The Netherlands), in accordance with Article 78(1) of Directive 2001/82/EC, as amended by Directive 2004/28/EC, informed the EMEA by a letter dated 25 August 2006 of its intention to vary the marketing authorisation and to add a new precautionary measure for 21 veterinary medicinal products containing alpha2-adrenoreceptor agonists authorised in The Netherlands.
Slovenian: Fakulteta Ter Beoordeling van Geneesmiddelen (Odbor za ocenjevanje zdravil, Nizozemska) je z dopisom z dne 25. avgusta 2006 skladno s členom 78(1) Direktive 2001/82/ES, kakor je bila spremenjena z Direktivo 2004/28/ES, obvestila agencijo EMEA o svojem namenu, da bo spremenila dovoljenje za promet z zdravilom in dodala nov previdnostni ukrep za 21 zdravil za uporabo v veterinarski medicini, odobrenih na Nizozemskem, ki vsebujejo agoniste adrenergičnih receptorjev alfa2.
English: The Committee considered that specific precautionary measures should be reflected in the product literature of concerned products containing alpha2-agonists.
Slovenian: Odbor je menil, da morajo biti v gradivu zadevnih zdravil, ki vsebujejo agoniste adrenergičnih receptorjev alfa2, navedeni posebni previdnostni ukrepi .
English: The extrapolation of the proposed warnings for one alpha2-adrenoreceptor agonist to other alpha2adrenoreceptor agonists was considered justified, since the pharmacological mode of action is the same and because several of the substances have shown similar effects in humans.
Slovenian: Predlagatelj je menil, da je uporaba opozoril, ki so bila predlagana za enega od agonistov adrenergičnih receptorjev alfa2, tudi pri drugih agonistih adrenergičnih receptorjev alfa2 upravičen, ker imajo te snovi enak farmakološki način delovanja in ker je več teh snovi pokazalo podobne učinke pri ljudeh.
English: 1 Article 78 of Directive 2001/82/EC, as amended See Annex I for the complete list of concerned products
Slovenian: 1 Člen 78 Direktive 2001/82/ES, kakor je bila spremenjena.
English: Written explanations were provided by the Marketing Authorisation Holders on 13 October 2006.
Slovenian: Imetniki dovoljenj za promet z zdravilom so predložili pisne razlage dne 13. oktobra
English: EU/1/11/671/001
Slovenian: EU/1/11/671/001 Xiapex
English: 1 vial + 1 vial
Slovenian: 1 viala + 1 viala
English: 0.9 mg Powder and solvent for solution for injection
Slovenian: 0,9 mg Prašek in vehikel za raztopino za injiciranje
English: powder: 3 ml solvent: 5 ml
Slovenian: prašek: 3 ml vehikel: 5 ml
English: Intralesional use powder: vial (glass) solvent: vial (glass)
Slovenian: Intralezijska uporaba prašek: viala (steklena) vehikel: viala (steklena)
English: Package size
Slovenian: velikost pakiranja
English: Content (concentration)
Slovenian: (Izmišljeno) ime jakost farmacevtska oblika pot uporabe ovojnina vsebina (koncentracija)
English: Outcome of a procedure under Article 33(4) of Directive 2001/82/EC, as amended
Slovenian: Izid postopka v skladu s členom 33(4) Direktive 2001/82/ES, kakor je bila spremenjena
English: The European Commission issued a decision on 28 August 2015.
Slovenian: Evropska komisija je sklep izdala 28. avgusta 2015.
English: The company wanted the authorisation to be recognised in other EU Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Iceland, Ireland, Italy, Latvia, Lithuania, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the United Kingdom).
Slovenian: Družba je želela, da bi bilo dovoljenje za promet z zdravilom priznano v drugih državah članicah EU (v zadevnih državah članicah, ki so v tem primeru Avstrija, Belgija, Bolgarija, Hrvaška, Ciper, Češka republika, Estonija, Finska, Nemčija, Grčija, Islandija, Irska, Italija, Latvija, Litva, Nizozemska, Poljska, Portugalska, Romunija, Slovaška, Slovenija, Švedska in Združeno kraljestvo).
English: What are the conclusions of the CVMP?
Slovenian: Kakšni so zaključki odbora CVMP?
English: Veterinary Medicines Division
Slovenian: Oddelek za zdravila za uporabo v veterinarski medicini
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 August 2015
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28.
English: However, the Member States were not able to reach an agreement and the National Food Chain Safety Office of Hungary referred the matter to the CVMP for arbitration on 24 October 2014.
Slovenian: Vendar države članice niso mogle doseči soglasja, zato je madžarski nacionalni urad za varnost prehrambne verige 24. oktobra 2014 zadevo napotil na odbor CVMP v arbitražo.
English: On 3 June 2015, the European Medicines Agency (the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Coglapix suspension for injection for pigs.
Slovenian: Evropska agencija za zdravila je 3. junija 2015 zaključila arbitražni postopek, do katerega je prišlo zaradi nesoglasja med državami članicami Evropske unije (EU) glede izdaje dovoljenja za promet z zdravilom Coglapix suspenzija za injiciranje za prašiče.
English: The grounds for the referral were concerns raised by Italy that the efficacy of Coglapix has not been adequately demonstrated, that the benefit of the vaccine under practical conditions of use has not been demonstrated and that the results obtained from duration of immunity studies were inconsistent.
Slovenian: Razlog za napotitev so bili pomisleki Italije v zvezi s tem, da učinkovitost zdravila Coglapix ni bila ustrezno dokazana, da korist cepiva v praktičnih pogojih uporabe ni bila dokazana in da so med študijami trajanja imunosti pridobili nasprotujoče si rezultate.
English: The vaccine is intended for active immunisation of pigs against pleuropneumonia caused by A. pleuropneumoniae serotypes 1 and 2, in order to reduce the clinical signs and lung lesions associated with the disease.
Slovenian: Namenjeno je aktivni imunizaciji prašičev proti plevropnevmoniji, ki jo povzročata serotipa 1 in 2 A. pleuropneumoniae, s čimer se zmanjšajo klinični znaki in pljučne lezije, povezani s to boleznijo.
English: The vaccine contains five formaldehyde-inactivated strains of Actinobacillus pleuropneumoniae.
Slovenian: Cepivo vsebuje pet s formaldehidom inaktiviranih sevov bacila Actinobacillus pleuropneumoniae.
English: The product information for Coglapix in Hungary should also be amended.
Slovenian: Spremeniti je treba tudi informacije o zdravilu Coglapix na Madžarskem.
English: Ceva-Phylaxia Veterinary Biologicals Co. Ltd. submitted an application for Coglapix for mutual recognition on the basis of the initial authorisation granted by Hungary.
Slovenian: Družba Ceva-Phylaxia Veterinary Biologicals Co. Ltd. je predložila vlogo za medsebojno priznavanje zdravila Coglapix na podlagi prvotnega dovoljenja za promet, izdanega na Madžarskem.
English: Hence, the relevant sections of the Summary of Product Characteristics and package leaflet should be amended in order to reflect this.
Slovenian: Zadevna poglavja povzetka glavnih značilnosti zdravila in navodila za uporabo je treba zato ustrezno spremeniti.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Coglapix outweigh its risks, and the marketing authorisation granted in Hungary can be recognised in other Member States of the EU (see below).
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Coglapix večje od z njim povezanih tveganj ter da se lahko dovoljenje za promet, izdano na Madžarskem, prizna v drugih državah članicah EU (gl. spodaj).
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that the benefits of Coglapix outweigh its risks, and recommended that the marketing authorisation be granted in all concerned Member States.
Slovenian: Odbor CVMP je glede na oceno trenutno razpoložljivih podatkov in znanstveno razpravo znotraj odbora sklenil, da koristi zdravila Coglapix odtehtajo z njim povezana tveganja, in priporočil, da se dovoljenje za promet izda v vseh zadevnih državah članicah.
English: Based on the data presented it was concluded that following vaccination of pigs with Coglapix reduction of clinical signs and lung lesions associated with the disease has been demonstrated in laboratory efficacy studies, although some concerns on the statistical significance of the results still remain.
Slovenian: Na podlagi predloženih rezultatov je odbor zaključil, da so po cepljenju prašičev z zdravilom Coglapix v laboratorijskih študijah učinkovitosti dokazali zmanjšanje kliničnih znakov in pljučnih lezij, povezanih s to boleznijo, čeprav so še vedno prisotni pomisleki glede statistične pomembnosti rezultatov.
English: The CVMP also recommended that the product information for the medicine in Hungary be amended.
Slovenian: Priporočil je tudi, da se informacije o tem zdravilu na Madžarskem spremenijo.
English: Duration of immunity was established for both serotypes (1 and 2) up to 16 weeks after vaccination according to the results of relevant challenge studies.
Slovenian: Glede na rezultate provokacijskih študij je bilo za oba serotipa (1 in 2) ugotovljeno trajanje imunosti do 16 tednov po cepljenju.
English: Why was Coglapix suspension for injection for pigs reviewed?
Slovenian: Zakaj je bilo zdravilo Coglapix suspenzija za injiciranje za prašiče pregledano?
English: Coglapix is an inactivated bacterial vaccine against porcine actinobacillosis.
Slovenian: Zdravilo Coglapix je inaktivirano bakterijsko cepivo proti prašičji aktinobacilozi.
English: What is Coglapix suspension for injection for pigs?
Slovenian: Kaj je zdravilo Coglapix suspenzija za injiciranje za prašiče?
English: 10 vials (multidose: 10 doses)
Slovenian: 10 vial (večkratni odmerek:
English: Content (concentration) Pack size
Slovenian: Vsebina (koncentracija)
English: 10 vials (monodose)
Slovenian: 10 vial (enkratni odmerek)
English: Route of administration
Slovenian: Pot uporabe Stična ovojnina
English: 10785 Berlin Germany
Slovenian: 10785 Berlin Nemčija
English: 243 Messoghion Avenue 154 51 Neo Psychico Greece
Slovenian: 243 Messoghion Avenue 154 51 Neo Psychico Grčija
English: 28700 San Sebastián de los Reyes (Madrid), Spain
Slovenian: 28700 San Sebastián de los Reyes (Madrid), Španija
English: Via Nettunense, 90 Aprilia (LT), 04011, Italy
Slovenian: Via Nettunense, 90 Aprilia (LT), 04011, Italija
English: List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Slovenian: Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
English: Arquiparque - Miraflores 1495-131 ALGÉS Portugal
Slovenian: Arquiparque - Miraflores 1495-131 ALGÉS Portugalska
English: Rivium westlaan 142 2909 LD Capelle a/d IJssel The Netherlands
Slovenian: Rivium westlaan 142 2909 LD Capelle a/d IJssel Nizozemska
English: Boulevard de la Plaine 17 1050 Brussels Belgium
Slovenian: Boulevard de la Plaine 17 1050 Brussels Belgija
English: Vetenskapsvägen 10 191 90 Sollentuna, Sweden
Slovenian: Vetenskapsvägen 10 191 90 Sollentuna, Švedska
English: Berkshire SL6 0PH United Kingdom
Slovenian: Berkshire SL6 0PH Velika Britanija
English: John Wyeth & Brother Limited (trading as Wyeth Pharmaceuticals) Huntercombe Lane South Taplow, Maidenhead, Berks, SL6 0PH United Kingdom
Slovenian: John Wyeth & Brother Limited (trading as Wyeth Pharmaceuticals) Huntercombe Lane South Taplow, Maidenhead, Berks, SL6 0PH Velika Britanija
English: Stroupežnického 3191/17, 150 00 Praha Smíchov Czech Republic
Slovenian: Stroupežnického 3191/17, 150 00 Praha Smíchov Češka
English: Stroupežnického 3191/17, 150 00 Praha Smíchov, Czech Republic
Slovenian: Stroupežnického 3191/17, 150 00 Praha Smíchov, Češka
English: 4 g piperacillin equivalent to 4.17 g piperacillin sodium
Slovenian: 4 g piperacilina, ki ustreza 4,17 g natrijeve soli piperacilina
English: 0.5 g tazobactam equivalent to 0.5366 g tazobactam sodium
Slovenian: 0.5 g tazobaktama, ki ustreza 0,5366 g natrijeve soli tazobaktama
English: 2,085 g sodium piperacillin + 268,30 mg sodium tazobactam
Slovenian: 2,085 g natrijeve soli piperacilina + 268,30 mg natrijeve soli tazobaktama
English: TAZOCIN 4g/0.5g contains 2 active ingredients; piperacillin 4g and tazobactam 0.5g both present as sodium salts.
Slovenian: TAZOCIN 4g/0,5g vsebuje 2 zdravilni učinkovini; piperacilin 4 g in tazobaktam 0,5 g, obe v obliki natrijeve soli.
English: Tazocin® 4 g/ 500 mg 4 g/500mg
Slovenian: Tazocin® 4 g/ 500 mg
English: TAZOCIN 4,5 g prašek za raztopino za injiciranje ali infundiranje
Slovenian: TAZOCIN 4 g / 0,5 g prašek za raztopino za injiciranje ali infundiranje
English: TAZOCIN 2g/0.25g contains 2 active ingredients; piperacillin 2g and tazobactam 0.25g both present as sodium salts.
Slovenian: TAZOCIN 2g/0,25g vsebuje 2 zdravilni učinkovini; piperacilin 2 g in tazobaktam 0,25 g, obe v obliki natrijeve soli.
English: 4,170 g sodium piperacillin + 536,60 mg sodium tazobactam
Slovenian: 4,170 g natrijeve soli piperacilina + 536,60 mg natrijeve soli tazobaktama
English: 4000m g+500mg g
Slovenian: 4000mg +500mg g
English: 1 injection vial contains piperacillin sodium equivalent to 4.0g of piperacillin and tazobactam sodium equivalent to 0.5g of tazobactam.
Slovenian: 1 viala vsebuje natrijevo sol piperacilina, ki ustreza 4,0 g piperacilina in natrijevo sol tazobaktama, ki ustreza 0,5 g tazobaktama
English: Intravenous use 2 g piperacillinum / 0,25 g tazobactamum
Slovenian: 2 g piperacilina / 0,25 g tazobaktama
English: 0.5366 g tazobactam sodium equivalent to 0.500 g tazobactam and 4.170 g piperacillin sodium equivalent to 4.00 g piperacillin
Slovenian: 0,5366 g natrijeve soli tazobaktama, ki ustreza 0,500 g tazobaktama in 4,170 g natrijeve soli piperacilina, ki ustreza 4,00 g piperacilina
English: 4 g piperacillin (in form of piperacillin sodium) and 0,5 g tazobactam (in form of tazobactam sodium).
Slovenian: 4 g piperacilina (v obliki natrijeve soli piperacilina) in 0,5 g tazobaktama (v obliki natrijeve soli tazobaktama)
English: 2 g piperacillin (in form of piperacillin sodium) and 0,25 g tazobactam (in form of tazobactam sodium).
Slovenian: 2 g piperacilina (v obliki natrijeve soli piperacilina) in 0,25 g tazobaktama (v obliki natrijeve soli tazobaktama)
English: Piperacillin 2g and tazobactam250mg both present as sodium salts.
Slovenian: 2 g piperacilina in 250 mg tazobaktama, oba v obliki natrijeve soli
English: Tazocin 2,25 g, liofilizat pentru soluţie injectabilă/ perfuzabilă
Slovenian: Tazocin 2,25 g, liofilizat pentru soluţie injectabilă/ perfuzabilă liofilizirani prašek za raztopino za injiciranje ali infundiranje
English: Tazocin 4,5 g injekció 4.5g
Slovenian: Tazocin 4,5 g injekció
English: Tazocin 4,5 g, liofilizat pentru soluţie injectabilă/ perfuzabilă
Slovenian: Tazocin 4,5 g, liofilizat pentru soluţie injectabilă/ perfuzabilă liofilizirani prašek za raztopino za injiciranje ali infundiranje
English: Intravenous use 4 g piperacillinum / 0,5 g tazobactamum
Slovenian: 4 g piperacilina / 0,5 g tazobaktama
English: Sodium piperacillin and sodium tazobactam, equivalent to 4 g piperacillin and 500 mg tazobactam
Slovenian: 4 g/500mg prašek za raztopino za injiciranje natrijeva sol piperacilina in natrijeva sol tazobaktama, ki ustrezata 4 g piperacilina in 500 mg tazobaktama
English: 2.085 g sodium piperacillin equivalent to 2 g piperacillin and 0.2683 g sodium tazobactam equivalent to 0.250 g tazobactam.
Slovenian: 2,085 g natrijeve soli piperacilina, ki ustreza 2 g piperacilina in 0,2683 g natrijeve soli tazobaktama, ki ustreza 0,250 g tazobaktama